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Abstract 
Purpose 
HIV-infected subjects present increased levels of inflammatory cytokines and T-cell 
activation in the peripheral blood despite suppressive combination antiretroviral therapy 
which renders them at increased risk of premature aging. The purpose of the present work is 
to review existing evidence on the ways in which the anatomical and microbiological 
abnormalities of the gastrointestinal tract can represent a major cause of organ disease in 
HIV infection. 
Methods 
We conducted a systematic review of the Pubmed database for articles published from 2014 to 
2018. We included studies on inflammatory/activation biomarkers associated with cardiovascular 
and bone disease, neurocognitive impairment and serious non-AIDS events in HIV-infected 
subjects. We also included researches which linked peripheral inflammation/activation to the 
anatomical, immune and microbiological alterations of the gastrointestinal tract. 
Results 
Recent literature data confirm the association between non-infectious comorbidities and 
inflammation in HIV infection which may be driven by gastrointestinal tract abnormalities, 
specifically microbial translocation and dysbiosis. Furthermore, there is mounting evidence on the 
possible role of metabolic functions of the microbiota in the pathogenesis of premature aging in the 
HIV-infected population 
Conclusions 
Biomarkers need to be validated for their use in the management of HIV infection. Compounds 
which counteract microbial translocation, inflammation and dysbiosis have been investigated as 
alternative therapeutic strategies in viro-suppressed HIV-infected individuals, but appear to have 
limited efficacy, probably due to the multifactorial pathogenesis of non-infectious comorbidities in 
this setting. 
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HIV, inflammation and end-organ disease 
Infection with the Human Immunodeficiency Virus (HIV) can be considered an inflammatory 
disease [1]. If left untreated, viral replication leads to the loss of CD4+ T-cell counts and HIV 
infection progresses to the Acquired Immunodeficiency Syndrome (AIDS). Combination 
antiretroviral therapy (cART), i.e. the combined use of three, effective antiviral drugs which impede 
HIV replication, has drastically changed the natural course of infection by restoring CD4+ T-cell 
counts and hampering advancement of HIV-infected subjects to AIDS [2]. Literature has 
consistently shown, however, that inflammation and activation persist in the course of viro-
suppressive treatment, albeit at lower levels than those observed when the infection remains 
untreated [1]. Specifically, HIV-infected subjects on cART feature activation of innate (sCD14, 
sCD163) and adaptive (CD38+HLADR+) immunity, senescent immune phenotypes (low 
expression levels of CD28, elevated levels of CD57 and PD-1), impaired thymic output, persistence 
of HIV reservoirs, reduced antigen-specific responses and heightened levels of pro-inflammatory 
and coagulation markers (IL-6, d-dimer, high-sensitivity C Reactive Protein, CRP) [1].  
Interestingly, such chronic, low-grade inflammation presents immune abnormalities that 
characterize physiologic aging [3]. The so called “inflammaging” signature of viro-suppressed, 
HIV-infected subjects renders this population at risk of premature aging (cardiovascular, bone and 
renal disease as well as neurocognitive impairment) and death from non-infectious comorbidities 
[3].  
Inflammatory and activation biomarkers have been object of numerous studies for their exploitation 
in clinical practice in order to aid in the identification and management of HIV-infected subjects at 
risk of non-communicable diseases [4, 5]. Yet, despite these efforts, the lack of validation standards 
for the majority of biomarkers investigated and the multifactorial process behind it [6] are causing a 
dearth of parameters to support clinicians in their decisions.  
Microbial translocation from the gut lumen to the systemic circulation has been widely investigated 
as one of the possible causes of activation/inflammation linked to premature aging in HIV infection 
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[6]; furthermore, it triggered studies on the gastrointestinal tract as a major site of HIV pathogenesis 
and shed light on possible mechanisms to target for the elaboration of alternative therapeutic 
interventions [1]. 
The purpose of the present work is to review existing evidence on the ways in which the anatomical 
and microbiological abnormalities of the gastrointestinal tract can represent a major cause of organ 
disease in HIV infection. 
 
Microbial translocation-induced immune activation and inflammation are linked to non-
infectious comorbidities in HIV infection 
Microbial translocation, i.e. the passage of bacteria and microbial bioproducts (e.g. 
lipopolysaccharide, LPS, of Gram-negative microrganisms) through the gastrointestinal tract to the 
peripheral circulation, is a major cause of immune activation in HIV infection.   
Over a decade go, a seminal paper by Brenchley et al. described increased plasma levels of LPS in 
HIV-infected subjects and demonstrated their positive correlation with markers of innate and 
adaptive immunity [7]. Subsequent literature observations confirmed such finding and demonstrated 
high levels of microbial-induced immune activation in subjects with poor CD4+ T-cell recovery on 
cART [8, 9] as well as non-infectious comorbidities.  
In this respect, microbial translocation, inflammation and immune activation have been invariably 
associated with cardiovascular risk in the HIV-infected population [10]. In particular, various 
parameters have been linked to dyslipidemia [11-13], insulin insensitivity [11, 12], endothelial 
dysfunction [14], visceral fat accumulation, higher Framingham risk [11, 12, 15], subclinical artery 
disease [16-20] and biomarkers of cardiovascular disease in this setting [12], highlighting the 
possible common pathways that cardiovascular disease and HIV share in their pathogenesis. 
Similarly, osteopenia and osteoporosis in HIV-positive subjects may be driven by the inflamed and 
activated immune milieu which features infection [21-25]. While some reports confirm the 
association between immune biomarkers and impaired osteogenesis [25, 26]/mineral density [27, 
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28], others have however failed to detect such a link [29, 30]. Future studies are thus warranted to 
explore the true effects of activation/inflammation on bone mineral density and fractures in the 
HIV-infected population. 
More recently, inflammatory biomarkers have also been studied in the context of HIV-related 
neurocognitive disorders. A growing body of evidence shows that immune-mediated brain injury 
may contribute to cognitive impairment and structural brain abnormalities [31-36]. The clinical 
significance of these findings remains yet an open matter, as central nervous system activation and 
inflammation also feature asymptomatic individuals [37-39]. 
Finally, large cohort studies confirmed the above-mentioned findings by demonstrating that 
markers of microbial translocation (LPS,), immune activation (sCD14), inflammation (IL-6, sTNF-
RI, sTNF-RII, high-sensitivity CRP) and coagulation (d-dimer and sICAM-1) are independent 
predictors of mortality as well as AIDS and non-AIDS related morbidity in HIV infection [40-45].  
The most recent findings on biomarkers predicting non-infectious comorbidities, serious non-AIDS 
events (SNAEs) and death in cART-treated subjects are summarized in Table 1. 
 
The gut as a source of inflammation in HIV infection 
Suggestive evidence of microbial translocation being a cause of immune activation prompted the in-
depth study of the gut as a pathogenic site of HIV infection. 
At the very beginning of the epidemic HIV-related enteropathy with malabsorption and steathorrea 
in untreated individuals was described in literature and featured both jejunal (partial villus atrophy 
with crypt hyperplasia) and colonic abnormalities (focal cell degeneration near the crypt base) [46]. 
More recently, studies have shed light on the underlying mechanisms of HIV-related enteropathy by 
demonstrating that exposure of genital and intestinal epithelial cells to HIV can directly breach the 
integrity of mucosal epithelial barrier allowing for microbial translocation [47]. Furthermore, in the 
context of untreated infection, microbial-induced immune activation, measured by the levels of 
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soluble CD14 (sCD14) correlated with markers of intestinal damage, thus pointing to the gut as a 
possible source of systemic inflammation [48]. 
A solid bulk of evidence demonstrated that the anatomical defects of HIV-related enteropathy 
persist on cART. Indeed, a reduced expression of ileum and colonic gut junctional complex proteins 
(cadherins, claudins, occludins) features long-term treated subjects [49-51] and is linked to 
increased gut permeability and persistent levels of microbial translocation [51]. Moreover, the 
negative correlation between LPS-dependent immune activation (sCD14 plasma levels, peripheral 
CD8+CD38+ T-cell frequencies) and gut junctional proteins [49, 51] further highlights that GI tract 
defects may contribute to inflammation. In line with this finding, a cohort study showed that 
peripheral blood levels of intestinal fatty acid binding protein, marker of intestinal damage, and 
zonulin-1 are independent predictors of mortality in cART-treated subjects [52]. 
 
Another important alteration that occurs in the gastrointestinal tract which may fuel microbial 
translocation is the impairment of mucosal immunity: early studies highlighted the massive 
depletion of CD4+ T-cell at mucosal sites in all phases of HIV infection and their partial 
reconstitution in the course of treatment [46]. More recently, studies have focused on cell 
populations which safeguard mucosal surfaces, namely IL-17-producing subsets: indeed, IL-17 is a 
crucial cytokine for protection against infectious microbes [53] and epithelial maintenance occurs 
through wound repair [54-56]. Both innate (T) and adaptive (Th) IL-17 producing cells are lost in 
the natural course of HIV infection [57, 58]; while their frequencies may be restored by the 
introduction of early treatment, their function invariably remains impaired [46], thus possibly 
explaining the persistence of microbial translocation and structural defects of the gastrointestinal 
tract despite effective therapy. Many reports have indeed confirmed the inverse relationship 
between IL-17-producing cell frequencies and inflammation in untreated disease [46], yet whether 
functional defects of mucosal populations directly drive inflammation and activation in the 
periphery of subjects on cART has yet to be demonstrated. 
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Findings on impaired gut structure and mucosal immunity in the setting of HIV infection have 
prompted the study of the gut microbiota, given its role in the maturation of the gut barrier and 
control of immune homeostasis at mucosal sites [57].  
Early reports in naïve subjects identified an outgrowth of fecal P.aeurginosa and C. albicans as 
well as a reduction of bifidobacteria and lactobacilli; these alterations were linked to increased fecal 
calprotectin levels, marker of intestinal inflammation [46]. Subsequent studies confirmed a 
dysbiotic fecal microbiota in the course of HIV infection featuring the enrichment for 
Proteobacteria and skewing of the Bacteroidetes phylum with a Prevotella-rich/Bacteroides-poor 
profile [59-64], which is only partially restored by cART [65]. Importantly, HIV-related dysbiosis 
correlates with heightened T-cell and myeloid dendritic cell activation, lower mucosal IL-17/IL-22 
secretion, as well as inflammatory markers [59, 61]. In the attempt to demonstrate the mechanisms 
whereby the fecal microbiota causes peripheral T-cell activation and inflammation, a very recent 
study reported greater production of pro-inflammatory cytokines in monocyte cultures (TNF-ɑ, IL-
6, IFN-γ) and the selective activation of peripheral T-cells following culture stimulation with fecal 
bacterial communities in HIV infection [66].  
Taken together, literature studies convene that HIV-related dysbiosis may drive peripheral blood 
inflammation and may be thus implicated in organ disease. 
 
The metabolic pathways of a dysbiotic microbiome may drive inflammation and organ disease 
in HIV infection 
Technical advances have not only shed light on the composition of resident bacteria in HIV 
infection but also on the functional activity of the microbiota, which is critical to human health and 
disease [67].  
An early study showed differences between the relative abundance of several imputed metagenomic 
functions between untreated HIV-infected subjects and healthy controls, suggesting the impairment 
of the functional activity of the microbiota in HIV infection [68]. In line with this observation, 
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researches that followed showed that the microbiota is depleted in genes belonging to main 
energetic processes (pyruvate metabolism, glycolysis and gluconeogenesis) and amino acid 
metabolism [63] which could impact on cART-mediated reconstitution of CD4+ T-cells [69]. In 
addition, bacterial genera enriched in HIV-infected, untreated subjects were found to encode 
enzymes involved in tryptophan catabolism [70, 71], an independent predictor of non-AIDS 
comorbidities and death [52, 72], thus entailing that the dysbiotic bacteria in HIV infection may 
directly contribute to immunoactive tryptophan catabolism in HIV and negatively impact on overall 
mortality [70].  
Stemming from these findings, other intestinal microbiota-generated metabolites known to cause 
organ disease were explored in the setting of non-infectious comorbidties in HIV infection. In 
particular, trimethylamine-N-oxide (TMAO), a metabolite of phosphatidylcholine, was linked to 
plaque burden [73, 74], myocardial perfusion defects [75], coronary stenosis [76] in HIV-infected 
subjects. Although TMAO was independently associated with microbial translocation markers 
(LPS) [77] and macrophage activation (sCD14, CD163) [74, 77], a recent report failed to find a 
relationship between the metabolite and inflammation [78], suggesting its limited use as clinical 
marker of cardiovascular risk in HIV infection given possible confounders. 
Significant evidence exists in literature on the gut-brain axis, i.e. the bidirectional communication 
between the central and the enteric nervous system, linking emotional and cognitive centers of the 
brain with peripheral intestinal functions [79]. The production of bacterial metabolites represents a 
possible mechanism by which the intestinal microbiota interacts with the brain. In the setting of 
HIV infection, increased choline and N-acetyl aspartate were recently found in the brain of subjects 
with neurocognitive impairment [80]; with evidence currently lacking on the source of such 
metabolites, future studies are critical for addressing whether microbial-dependent metabolites play 
a role in the pathogenesis of neurocognitive disorders in HIV infection. 
In line with the findings of a link between the microbiota and the central nervous system, studies in 
the clinical setting of rheumatoid arthritis and inflammatory bowel disease have demonstrated the 
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existence of a gut-immune-skeletal axis in which alteration of the gut microbione induce an 
activated immune phenotype and inflammatory milieu which associates with bone loss [81]. Given 
the pathogenic and clinical features of HIV disease, further research should explore the effects of 
the microbiome/metabolome in HIV-relates osteopenia and osteoporosis. 
 
Open issues and future directions 
The present review focused on microbial translocation-induced activation and inflammation as a 
cause of premature aging in HIV disease. We highlighted the role of the gastrointestinal tract as a 
driver of inflammation: alterations of the gut epithelial barrier, mucosal immune populations and 
microbiome/metabolome all play a key role in causing and perpetuating low-grade inflammation 
which features the inflammaging phenotype of viro-suppressed HIV-infected individuals.  
Clinical questions remain as to whether any on the inflammatory biomarkers examined in the 
literature may be used as a screening tool to identify subjects at risk of developing non-infectious 
comorbidities. Inflammatory biomarkers lack validation standards and are not routinely measured in 
HIV-infected individuals; this leaves clinicians with the CD4+ T-cell count as the only reliable 
marker to assess subjects’ immune status, which nonetheless does not capture the “inflammaging” 
signature of cART-treated disease. Studies focusing on longitudinal cohorts with powered clinical 
endpoints are needed in order to exploit biomarkers of premature aging in the clinical practice.  
Another relevant aspect is how to turn-off microbial-driven inflammation. In this respect, work has 
been carried out in the attempt to reverse microbial translocation and dysbiosis. In humans, LPS-
antagonizing compounds (sevelamer), anti-inflammatory agents (mesalamine) and antibiotics 
(rifaximin) have lead to little/no effects on microbial translocation, inflammation and T-cell 
activation [46]. Similarly, the administration of pre/probiotics did not result in significant changes 
in inflammation/activation [46] and composition of the microbiome [82]. A possible explanation for 
the failure of these treatments is that they target a limited set of causes underlying a multifactorial 
process (i.e. microbial translocation, reservoirs, CMV co-infection) [6]. Future studies should aim at 
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combining several approaches in order to counteract the complex phenomenon of aging in HIV 
infection. 
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Table 1: Biomarkers linked to non-infectious comorbidities, serious non-AIDS events and death in cART-treated, HIV-infected subjects 
Clinical Event Study design Patient Population Aim Markers Main findings Reference 
CVD Cross-sectional 61 cART-treated  Investigate whether microbial 
translocation and monocyte 
activation associate with 
endovascular dysfunction, 
inflammation and altered 
coagulation. 
LPS, sCD14, hs-
CRP, d-dimer 
sCD14 associates with 
endovascular dysfunction 
in HIV. 
[14]  
 
CVD Cross-sectional 147 cART-treated  Explore the relationship between 
inflammation, T-cell/monocyte 
activation and coronary 
calcification/subclinical vascular 
disease. 
sCD14, sCD163, hs-
CRP, IL-6, sTNFR-
II, sVCAM-1, OPG, 
RANKL 
sCD14 independently 
associates with coronary 
artery calcification. 
[19] 
CVD Cross-sectional 252 cART-treated Explore the association of soluble 
biomarkers with patient 
demographics, HIV progression, 
components of the metabolic 
syndrome, viral co-infections,  
Framingham risk score and the 
VACS Index. 
IL-6, cystatin C, hs-
CRP, TNF-α, d-
dimer 
Elevated inflammation 
and coagulation  
associate with higher 
scores on risk 
stratification indices. 
[15] 
CVD Cross-sectional 242 cART-treated and 
348 uninfected controls 
 
Investigate the association of 
inflammatory markers with 
subclinical coronary artery disease. 
IL-6, sICAM-1, 
fibrinogen, d-dimer, 
hs-CRP, sTNFR I 
and II 
Higher inflammatory 
marker levels associated 
with greater prevalence 
of coronary stenosis. 
[16] 
CVD  149 cART-treated Determine the associations of 
markers of immune activation with 
atherosclerosis and mortality. 
IL-6, hs-CRP, 
sCD14, sCD163, d-
dimer, T cell 
activation (HLA-
DR/CD38) and 
senescence 
(CD57/CD28), 
monocytes subsets 
(CCR2/CX3CR1 
/CCR5) 
Monocyte CCR5 
expression and plasma 
IL-6 associate with 
atherosclerosis. IL-6 and 
carotid artery IMT 
associate with all-cause 
mortality. 
[17] 
CVD/Bone 
disorders 
Cross-sectional 94 cART-treated and 41 
uninfected controls 
Investigate the role of traditional 
factors, T-cell phenotype and 
osteoprotegerin in bone and 
cardiovascular disease. 
OPG, T cell 
activation (HLA-
DR/CD38) and 
senescence 
(CD57/CD28) 
OPG and T-cell 
activation/senescence 
linked to bone and 
cardiovascular disease. 
[28] 
Bone disorders Cross-sectional 142 cART-treated Determine the association between RANKL, OPG, Weak correlation [29] 
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bone health and inflammation, T-cell 
activation, and monocyte activation. 
sVCAM-1, sICAM-
1, IL-6, TNF-α, 
sTNFR I and II, hs-
CRP, d-dimer, 
sCD14, sCD163 
between BMD and 
markers of 
inflammation/immune 
activation . Bone 
resorption associated 
with ICAM-1 
Neurogognitive 
impairment 
Longitudinal  99 cART-treated Examine the relationship between 
mild HAND and CSF NFL/neopterin. 
Neopterin, NFL Mild HAND was 
associates with increased 
intrathecal immune 
activation. 
[35] 
Neurogognitive 
impairment 
Cross-sectional 41 cART-treated Investigate the role of cell-free 
mitochondrial DNA in the CSF. 
mitochondrialDNA, 
sCD14, TNF-α, IL-
6, IL-8, MCP-1, IP-
10, NFL 
Higher cell-free 
mitochondrial DNA is 
associates with 
inflammation  
[39] 
Neurogognitive 
Impairment 
Longitudinal  51 acutely-infected, cART-
treated and 18 uninfected 
controls 
Explore whether early cART impacts 
CD163 shedding, with possible 
implications on the CNS. 
sCD163 Early treatment reduces 
sCD163 which is linked 
to neuropsychological 
perfomances 
[32] 
 Neurogognitive 
Impairment 
Cross-sectional 90 cART-treated, 94 
uninfected controls 
Assess the impact of HIV on 
complex motor performances. 
d-dimer, IL-6, 
MCP-1, sCD14, 
TNF-α 
Inflammation accounts 
for worse complex motor 
skills. 
[36] 
Death Case-control 64 cases - 128 controls 
(LCOSA cohort) 
27 cases – 54 controls 
(SCOPE cohort) 
 
Assess immunologic predictors of 
mortality. 
IL-6, I-FABP, 
sCD14, hs-CRP, 
zonulin-1, sTNFR-
1, d-dimer, KT 
ratio, T cell 
activation 
(CD38/HLA-DR), 
exhaustion (PD1), 
senescence 
(CD57/CD28) 
Gut epithelial barrier 
dysfunction, innate 
immune activation, 
inflammation, 
independently predict 
mortality 
[52] 
SNAEs/death Case-control; 
longitudinal 
cART-treated: 
143 cases (non-AIDS events) 
315 controls 
 
Assess the role of biomarkers on 
disease outcomes. 
 
IL-6, IFN- γ, 
sCD14, IP10, 
sTNFR-1, sTNFR-
II, d-dimer 
T cell activation 
(CD38/HLA-DR), 
exhaustion (PD1) 
senescence 
(CD57/CD28) 
IL-6, sTNFR-I and II, 
sCD14,, plasma KT ratio, 
and d-dimer level 
associate with a higher 
risk of non–AIDS-related 
morbidity and mortality. 
[72] 
SNAEs Case-control; cART-treated: Investigate whether unchanged or sCD14, sCD163, Unchanged or slow rates [83] 
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longitudinal 39 cases (non-AIDS events) 
39 controls  
 
smaller decreases in systemic 
inflammation predict SNAEs. 
 
IL-6 
 
of decrease of sCD14 and 
IL-6, levels predict 
SNAEs. 
SNAEs Longitudinal  249 cART-treated Examine the longitudinal changes in 
biomarkers following cART their 
association with future non-AIDS 
events. 
IL-6, d-dimer Persistent elevation of d-
dimer levels associate 
with an increased risk of 
non-AIDS events. 
[43] 
SNAEs/death Cross-sectional 3756 cART-treated: 
1748 SMART, 1446 
ESPRIT, 572 SILCAAT 
cohorts 
Examine the associations of 
biomarkers with SNAEs/death in 3 
large cohorts. 
IL-6, d-dimer, hs-
CRP 
IL-6 and d-dimer are 
independently associatee 
with SNAEs. 
[42] 
Legend: 
CVD, cardiovascular disease; cART, combination antiretroviral therapy; LPS, lipopolysaccharide; sCD14, soluble sCD14; hs-CRP, high-sensitivity C Reactive Protein; sCD163, 
soluble 163; sTNFR, soluble Tumor Necrosis Factor Receptor; sVCAM-1, vascular cell adhesion molecule-1; OPG, Osteoprotegerin; RANKL, RANK Ligand;  TNF-α, Tumor 
Necorsi Factor-α ; IL-, Interleukin; sICAM-1, intracellular adhesion molecule-1; IMT, Intima Media Thickness; CSF, Cerebro-spinal Fluid; NFL, Neurofilament Light protein; 
HAND, HIV-Associated Neurocognitive Disorder; MCP-1, Monocyte chemoattractant protein-1;  IP-10, Interferon- γ-induced protein 10; IFN- γ, Interferon-γ; I-FABP, 
Intestinal fatty-acid binding protein;  KT, Kynurenine tryptophan; SNAE, Serious Non-AIDS Event.
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